Back to ProShare Advisors LLC ProShare Advisors LLC

ADMA

27 quarters

Position history for ProShare Advisors LLCProShare Advisors LLC's holdings in ADMA Biologics Inc

Yes. ProShare Advisors holds 39,323 shares of ADMA (ADMA Biologics), worth $394,410, as of its Q3 2026 13F filing. It reduced the position by 1,195 shares (-3.0%) from Q2 2026. ProShare Advisors has held ADMA since Q4 2021, across 20 quarterly 13F filings.

Current Value

$394,410

Current Shares

39,323

Total Value Change

+$315,410

Total Shares Change

+19,671

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q3
Latest
Decreased
39,323
-3.0%
$394,4100.0%$10.03
0
2026-Q2
Decreased
40,518
-13.4%
$339,1350.0%$8.37
0
2026-Q1
Decreased
46,794
-15.9%
$421,6140.0%$9.01
0
2025-Q4
Increased
55,655
+6.4%
$1M0.0%$18.24
27
2025-Q3
Decreased
52,293
-14.0%
$766,6170.0%$14.66
0
2025-Q2
Decreased
60,789
-6.3%
$1.1M0.0%$18.21
0
2025-Q1
Decreased
64,881
-18.2%
$1.3M0.0%$19.84
0
2024-Q4
Increased
79,286
+30.2%
$1.4M0.0%$17.15
32
2024-Q3
Increased
60,911
+42.1%
$1.2M0.0%$19.99
34
2024-Q2
Decreased
42,863
-21.1%
$479,2090.0%$11.18
0
2024-Q1
Increased
54,293
+9.2%
$358,3340.0%$6.60
26
2023-Q4
Increased
49,723
+18.2%
$224,7480.0%$4.52
27
2023-Q3
Increased
42,068
+0.7%
$150,6040.0%$3.58
22
2023-Q2
Increased
41,778
+4.6%
$154,1610.0%$3.69
23
2023-Q1
Decreased
39,957
-0.6%
$132,2580.0%$3.31
0
2022-Q4
Increased
40,188
+8.6%
$155,9290.0%$3.88
24
2022-Q3
Increased
37,004
+2.3%
$90,0000.0%$2.43
22
2022-Q2
Increased
36,170
+78.5%
$71,0000.0%$1.98
32
2022-Q1
Decreased
20,265
-26.5%
$37,0000.0%$1.83
0
2021-Q4
New
27,576
-
$39,0000.0%$1.41
28
2021-Q2
Exited
0
-100.0%
$00.0%$1.60
0
2021-Q1
Increased
17,612
+20.6%
$31,0000.0%$1.76
23
2020-Q4
Decreased
14,603
-31.4%
$28,0000.0%$1.95
0
2020-Q3
Decreased
21,292
-3.1%
$51,0000.0%$2.39
0
2020-Q2
Increased
21,978
+82.0%
$64,0000.0%$2.93
32
2020-Q1
Decreased
12,073
-38.6%
$35,0000.0%$2.88
0
2019-Q4
New
19,652
-
$79,0000.0%$4.00
30

Other major holders of ADMA: BlackRock, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used